Research programme: antiviral therapeutics - Cocrystal Pharma

Drug Profile

Research programme: antiviral therapeutics - Cocrystal Pharma

Alternative Names: CC 2850; CC-1845; CC-2068; CC-2069; CC-31326; CC-42344; CDI-244

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cocrystal Discovery
  • Developer Cocrystal Pharma Inc
  • Class Antivirals; Small molecules
  • Mechanism of Action Endonuclease inhibitors; Enzyme modulators; Hepatitis C virus NS 5 protein inhibitors; Polymerase inhibitors; RNA replicase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis C; Influenza virus infections; Norovirus infections
  • Research Ebola virus infections; Hepatitis B; Human papillomavirus infections
  • No development reported Dengue; Rhinovirus infections

Most Recent Events

  • 22 Mar 2018 Cocrystal Pharma plans a phase I trial for Influenza virus infections for CC 42344 in in fourth quarter of 2018
  • 28 Jan 2018 No recent reports of development identified for research development in Dengue in USA (PO)
  • 28 Jan 2018 No recent reports of development identified for research development in Rhinovirus-infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top